Pulmonary vascular resistance

1. Acid ceramidase gene therapy decreases pulmonary vascular resistance in Rodentia (4.44 ± 0.71 mm Hg vs 6.79 ± 0.85 mm Hg).

   “but not in animals receiving Anc80L65.AC (4.44 ± 0.71 mm Hg, p < 0.001).”

   Animalspulmonary hypertension modelintratracheal administrationpulmonary artery8 weeks

   Acid ceramidase gene therapy ameliorates pulmonary arterial hypertension with right heart dysfunction

   Respiratory research·Aug 11, 2023

2. Acid ceramidase gene therapy decreases pulmonary vascular resistance in rodents (4.44 ± 0.71 mm Hg vs 6.79 ± 0.85 mm Hg (p < 0.001)).

   “significant increase in pulmonary vascular resistance in the saline-treated (6.79 ± 0.85 mm Hg) and empty capsid (6.94 ± 0.47 mm Hg) groups, but not in animals receiving Anc80L65.AC (4.44 ± 0.71 mm Hg, p < 0.001)”

   Animalsin rodent PAH model (pneumonectomy + Sugen)Anc80L65.AC8 weeks

   Acid Ceramidase Gene Therapy Ameliorates Pulmonary Arterial Hypertension with Right Heart Dysfunction

   Research Square·Aug 9, 2022Preprint

More on Acid ceramidase gene therapy

1. Glycine decreases pulmonary vascular resistance in pigs (879 +/- 127 dyn x sec x cm(-5) [LPD-glyc] vs 663 +/- 191 dyn x sec x cm(-5) [IV-glyc] vs 1310 +/- 319 dyn x sec x cm(-5)).

   “Pulmonary vascular resistance remained significantly (P < .01) lower in both glycine groups when compared with controls.”

   Animalsafter 24 hours of cold ischemialung3.75 g

   Glycine intravenous donor preconditioning is superior to glycine supplementation to low-potassium dextran flush preservation and improves graft function in a large animal lung transplantation model after 24 hours of cold ischemia

   The Journal of thoracic and cardiovascular surgery·Mar 1, 2006

More on Glycine

1. Pulmonary vascular resistance impairs prognosis in humans (6-year event-free rates, PVR >3 Wood units versus PVR ≦3 Wood units, previous registry: 72.9% versus 61.4%; current registry: 75.2% versus 55.4%).

   “Stratified analyses using propensity score-matched data demonstrated a significant association between PVR >3 Wood units and prognosis in patients with Group 2 PH”

   HumansGroup 2 PH

   Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry

   Journal of the American Heart Association·Mar 20, 2026

1. Pulmonary vascular resistance raises the risk of atrial fibrillation in humans (HR 1.38, 95% CI 1.00-2.08).

   “and PVR (HR, 1.38; 95% CI, 1.00-2.08) independent of LA and LV structure and function”

   Humansindependent of LA and LV structure and functionmedian, 6.3 yearsn = 2,246

   Association of Right Ventricular Afterload With Atrial Fibrillation Risk in Older Adults: The Atherosclerosis Risk in Communities Study

   Chest·May 11, 2022

More on Atrial fibrillation